Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
After hours: January 3 at 6:33:04 PM EST Loading Chart for APVO ...
Mipletamig is under clinical development by Aptevo Therapeutics and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase II drugs for ...
After hours: January 3 at 6:33:04 p.m. EST ...
After hours: 29 November at 4:57 pm GMT-5 ...
This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...
and 4-1BBx5T4 bispecific antibody ALG.APV-527 – being co-developed with Aptevo Therapeutics – which is in early clinical development. Last month, Alligator reported updated results from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback